Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of HT-101 Injection in Healthy Subjects and Patients with Chronic Hepatitis B Virus Infection: a Randomized, Double-blind, Placebo-controlled, Single and Multiple Doses, and Dose Escalation Phase 1 Clinical Study
Latest Information Update: 30 Dec 2024
At a glance
- Drugs HT 101 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; First in man
Most Recent Events
- 16 Aug 2024 New trial record